ABSTRACT
SAŽETAK

Multipli mijelom je maligna bolest plazmocita kostne srži. Obično je ograničen na kostnu srž, ali u retkim sluča-jevima kod pacijenata se može javiti ektramedularna lokalizacija bolesti. Zahvaćenost limfnh čvorova je retko i može predstavljati dijagnostički izazov.
Prikazali (1) . Although it usually is confined to the bone marrow and surrounding bones, some patients develop extramedullary disease (EMD) in the form of soft tissue plasmacytomas. Local growth of MM within the bone marrow combined with direct spreading of the disease into the soft tissue surrounding the involved bones is the main mechanism of EMD development. Haematogenous metastatic spreading is the second, not so common mechanism of EMD development (2) . Haematogenous spreading usually involves skin, liver, breast, or kidney (3) and in rare cases, lymph nodes (less than 1% of all EMD) (4) . Here, we present the case of a patient with EMD involving the retroperitoneal and mesenteric lymph nodes at the time of MM diagnosis.
CASE REPORT
A previously healthy 36-year-old man initially presented with abdominal pain and discomfort reported to have been occurring over the previous two months. Ultrasound revealed abdominal lymphadenopathy, and the patient was referred to the Hematology Department of Clinical Centre in Kragujevac with suspicion of a lymphoproliferative disease. Abdominal computed tomography showed mesenteric and retroperitoneal lymphadenopathy (the largest lymph node was 57 mm in diameter) without the formation of a conglomerate mass ( Figure 1 ). Superficial lymph nodes were not palpable. The patient's haemoglobin was 8.3 g/100 ml; white blood cell and platelets counts were 5.100 and 213.000 per cubic millimetre, respectively; and the erythrocyte sedimentation rate was 104 mm/h. His serum lactate-dehydrogenase level was elevated at 331 U/L (normal range: 94-250 U/L) as was his serum globulin at 42 g/l (normal range: 20-35 g/l); other values for biochemical analyses and parameters of haemostasis were within the normal range. Tests for HIV (human immunodeficiency virus) and HCV (hepatitis C virus) antibodies and HBV (hepatitis B virus) antigen were negative. Explorative laparotomy was performed, and biopsies of the abdominal lymph node and infiltrated colon were taken. Histological examination of the specimens revealed diffuse infiltration of the lymph node and colon with regular plasma cells, which were positive for CD79α, CD38, CD138, kappa light chain and VEGF2 (Figure 2 1-4) , and thalidomide (100 mg daily), followed by high doses of melphalan with autologous haematopoietic cell transplantation. Bone marrow biopsy after treatment did not show any signs of disease, and paraproteins were not detected by serum protein electrophoresis. A CT scan showed enlarged lymph nodes in the abdomen, but PET CT scans did not detect any metabolically active foci. As such, complete remission was achieved. Three years after the completion of therapy, the patient remained in complete remission. 
DISCUSSION
The incidence of EMD seems to have increased over recent years. At the time of the diagnosis, 7-18% of patients with MM had EMD according to different studies (5) (6) (7) (8) . An additional 6% to 20% of patients develop plasmacytomas later in the course of disease (7, 8) . One explanation for this could be the more frequent use and availability of sensitive imaging techniques, such as magnetic resonance imaging, computed tomography, and occasionally positron emission tomography. Additionally, the prolonged survival of myeloma patients due to the introduction of novel agents, such as proteasome inhibitors and immune modulators, in treatment has increased the incidence of EMD (5) .
The infiltration of lymph nodes by malignant plasma cells could occur as a result of primary lymph node plasmacytomas. These can be diagnosed only after the exclusion of primary bone marrow involvement (9) , and would represent a rare localization of primary plasmacytomas. On the other hand, lymph nodes could be involved in the extramedullary spreading of myeloma (10) . The extramedullary involvement of lymph nodes is not frequently detected in living patients (3, 11, 12) but is discovered more often in autopsies (13) . An explanation for this could be the absence of symptoms in most cases. The patient that we presented here had dyspepsia and occasionally gastric pain that together with a high value of C-reactive protein and a high erythrocyte sedimentation rate led to further investigation, which revealed mesenteric and retroperitoneal lymphadenopathy, first by ultrasound and then with computed tomography, after which a diagnosis was established based on the results of the biopsies.
Our patient was treated with a thalidomide-based regimen in six cycles, followed by autologous haematopoietic cell transplantation, and complete remission was achieved. Studies have shown that extramedullary progression of MM is associated with a worse prognosis (5, 6) . In fact, patients with EMD at the time of the diagnosis, despite a lower International Scoring System (ISS) score, have poorer outcome regardless of first-line treatment (14) . For de novo EMD patients who are eligible for stem cell transplantation, a triplet induction therapy approach (bortezomiblenalidomide-dexamethasone) is suggested, followed by high-dose melphalan with autologous haematopoietic cell transplantation, triplet consolidation therapy (bortezomiblenalidomide-dexamethasone), and maintenance treatment consisting of at least lenalidomide (15) . Using thalidomide in the treatment of patients with EMD is controversial. Rosinol et al showed that patients with EMD did not respond to therapy with single agent thalidomide (16) , which correlates with other studies that showed EMD progression under thalidomide treatment, despite a good bone marrow response (17, 18) . In contrast, some cases of EMD responded well to thalidomide and dexamethasone therapy (19, 20) . Based on the patient's age, good cardiac ejection fraction, large tumour mass, and contraindications for using bortezomib and lenalidomide as first-line therapy, we started to treat the patient with a combination of thalidomide, dexamethasone and doxorubicin, followed by high doses of melphalan and autologous haematopoietic cell transplantation. Using this regimen, the patient achieved complete remission.
To conclude, extramedullary myeloma is a heterogeneous entity that affects almost 15% of MM patients during their overall disease course. The clinical presentation can be very unusual and efforts should be made to optimally detect extramedullary disease. PET-CT is an important tool at diagnosis and during follow-up. After the treatment of EMD, patients are still exceedingly poorly managed, which is particularly challenging. It is necessary to define innovative treatment strategies to improve the outcomes of this subgroup of myeloma patients.
